Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

4,003 public trials 391 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1237.5.01038 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 1237.5.01036 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 1237.5.01015 Boehringer Ingelheim Investigational Site Boulder, Colorado, United States
  • 1237.5.01024 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
View all 239 locations
View Trial Details
Completed

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1237.20.1204 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 1237.20.1203 Boehringer Ingelheim Investigational Site Easley, South Carolina, United States
  • 1237.20.1201 Boehringer Ingelheim Investigational Site Greenville, South Carolina, United States
  • 1237.20.1202 Boehringer Ingelheim Investigational Site Spartanburg, South Carolina, United States
View all 29 locations
View Trial Details
Completed

Japan Long-term Safety for Tiotropium Plus Olodaterol

NCT01536262

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1237.22.81015 Boehringer Ingelheim Investigational Site Chiyoda-ku, Tokyo, Japan
  • 1237.22.81023 Boehringer Ingelheim Investigational Site Chuo-ku, Tokyo, Japan
  • 1237.22.81009 Boehringer Ingelheim Investigational Site Hamamatu, Shizuoka, Japan
  • 1237.22.81011 Boehringer Ingelheim Investigational Site Kishiwada, Osaka, Japan
View all 24 locations
View Trial Details
Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

NCT01040403

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1237.18.02004 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada
  • 1237.18.02005 Boehringer Ingelheim Investigational Site Grimsby, Ontario, Canada
  • 1237.18.02001 Boehringer Ingelheim Investigational Site Mississauga, Ontario, Canada
  • 1237.18.02008 Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada
View all 33 locations
View Trial Details
Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

NCT01712516

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigative Site Huntsville, Alabama, United States
  • Novartis Investigative Site *See Various Dept.'s*, Arizona, United States
  • Novartis Investigative Site Tempe, Arizona, United States
  • Novartis Investigative Site Buena Park, California, United States
View all 95 locations
View Trial Details

Related conditions